Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Objective: This study aimed to assess the efficacy and safety of camrelizumab plus apatinib in patients with resectable hepatocellular carcinoma (HCC) as neoadjuvant therapy. Methods: Initially, 20 patients with HCC were screened and 18 patients with resectable HCC were enrolled in this open-label, single-arm, phase II clinical trial. Patients received three cycles of neoadjuvant therapy including three doses of camrelizumab concurrent with apatinib for 21 days followed by surgery. Four to 8 weeks after surgery, patients received eight cycles of adjuvant therapy with camrelizumab in combination with apatinib. Major pathological reactions (MPR), complete pathological reactions (pCR), objective response rate (ORR), relapse-free survival (RFS), and adverse events (AE) were assessed. In addition, cancer tissue and plasma samples were collected before and after treatment, and genetic differences between responding and non-responding lesions were compared by tumor immune microenvironment (TIME) analysis, circulating tumor DNA (ctDNA) analysis and proteomics analysis. Results: In 18 patients with HCC who completed neoadjuvant therapy, 3 (16.7%) and 6 (33.3%) patients with HCC reached ORR based on Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and modified RECIST criteria, respectively. Of the 17 patients with HCC who received surgical resection, 3 (17.6%) patients with HCC reported MPR and 1 (5.9%) patient with HCC achieved pCR. The 1-year RFS rate of the enrolled patients was 53.85% (95% CI: 24.77% to 75.99%). Grade 3/4 AEs were reported in 3 (16.7%) of the 18 patients, with the most common AEs being rash (11.1%), hypertension (5.6%), drug-induced liver damage (5.6%), and neutropenia (5.6%) in the preoperative phase. The 289 NanoString panel RNA sequencing showed that TIME cell infiltration especially dendritic cells (DCs) infiltration was better in responding tumors than in non-responding tumors. Our results of ctDNA revealed a higher positive rate (100%) among patients with HCC with stage IIb–IIIa disease. When comparing patients with pCR/MPR and non-MPR, we observed more mutations in patients who achieved pCR/MPR at baseline (6 mutations vs 2.5 mutations, p=0.025). Patients who were ctDNA positive after adjuvant therapy presented a trend of shorter RFS than those who were ctDNA negative. Proteomic analysis suggested that abnormal glucose metabolism in patients with multifocal HCC might be related to different sensitivity of treatment in different lesions. Conclusion: Perioperative camrelizumab plus apatinib displays a promising efficacy and manageable toxicity in patients with resectable HCC. DCs infiltration might be a predictive marker of response to camrelizumab and apatinib as well as patients’ recurrence. ctDNA as a compose biomarker can predict pathological response and relapse. Abnormal glucose metabolism in patients with multifocal HCC may be related to different sensitivity of treatment in different lesions. Trial registration number: NCT04297202.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preoperative use of ICIs in patients with hepatocellular carcinoma has been explored in several small, early-phase studies, in which heterogeneous therapeutic combinations were tested, mainly with safety and feasibility being the primary endpoints assessed.7–12”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of ICIs as a neoadjuvant treatment before liver resection for patients with hepatocellular carcinoma has been explored in several single-centre phase 1 and 2 clinical trials.”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, none of these studies were individually powered to robustly investigate predictive factors of efficacy from neoadjuvant ICI therapy, particularly with regards to long-term survival outcomes, including relapse-free survival.”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clinical studies have been inconsistent with the choice of a cutoff of major pathological response, with some studies adopting 70%7,8,25 and other studies adopting 90%,9,10 and the 70% threshold has not received multicentre validation.”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Collectively, these pioneering studies have shown the safety and feasibility of a perioperative ICI treatment approach.7–12,25”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
fastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing
Talevich, E., Shain, A. H., Botton, T., & Bastian, B. C. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004873 · Cited by 2,094
Liquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191
Finn, R. S., Ikeda, M., Zhu, A. X., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00808 · Cited by 1,167
Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
Gao, Q., Zhu, H., Dong, L., Shi, W., Chen, R., Song, Z., Huang, C., Li, J., Dong, X., Zhou, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.052 · Cited by 1,096
Self-citationInterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines
Li, Q., & Wang, K. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.01.004 · Cited by 1,038
Self-citationVarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
Lai, Z., Markovets, A., Ahdesmaki, M., Chapman, B., Hofmann, O., McEwen, R., Johnson, J., Dougherty, B., Barrett, J. C., & Dry, J. R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw227 · Cited by 970
Recurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis
Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M., & Roayaie, S. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000710 · Cited by 903
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 864
Science Translational Medicine
(2013) · Science Translational Medicine · doi:10.1126/scitranslmed · Cited by 859
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
Gene expression markers of Tumor Infiltrating Leukocytes
Danaher, P., Warren, S., Dennis, L., D’Amico, L., White, A., Disis, M. L., Geller, M. A., Odunsi, K., Beechem, J., & Fling, S. P. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0215-8 · Cited by 806
Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.010 · Cited by 716
The diagnosis and treatment of hepatocellular carcinoma
Hartke, J., Johnson, M., & Ghabril, M. (2017) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2016.12.011 · Cited by 670
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
Zhou, J., Sun, H.-C., Wang, Z., Cong, W.-M., Wang, J.-H., Zeng, M.-S., Yang, J.-M., Bie, P., Liu, L.-X., Wen, T.-F., et al. (2018) · Liver Cancer · doi:10.1159/000488035 · Cited by 649
Self-citationSynergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
Xu, J., Shen, J., Gu, S., Zhang, Y., Wu, L., Wu, J., Shao, G., Zhang, Y., Xu, L., Yin, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2571 · Cited by 565
cGAS is essential for the antitumor effect of immune checkpoint blockade
Wang, H., Hu, S., Chen, X., Shi, H., Chen, C., Sun, L., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621363114 · Cited by 563
Torzilli, G., Belghiti, J., Kokudo, N., Takayama, T., Capussotti, L., Nuzzo, G., Vauthey, J.-N., Choti, M. A., De Santibanes, E., Donadon, M., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31828329b8 · Cited by 496
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
Magbanua, M. J. M., Swigart, L. B., Wu, H.-T., Hirst, G. L., Yau, C., Wolf, D. M., Tin, A., Salari, R., Shchegrova, S., Pawar, H., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.007 · Cited by 462
Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma
Erstad, D. J., & Tanabe, K. K. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07227-9 · Cited by 428
Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
Ye, Q., Ling, S., Zheng, S., & Xu, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1043-x · Cited by 379
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Yoo, C. H., Gojenola, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0011-0 · Cited by 365
Ho, W. J., Zhu, Q., Durham, J., Popovic, A., Xavier, S., Leatherman, J., Mohan, A., Mo, G., Zhang, S., Gross, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00234-4 · Cited by 360
Yin, L., Li, H., Li, A.-J., Lau, W. Y., Pan, Z.-Y., Lai, E. C. H., Wu, M.-C., & Zhou, W.-P. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.012 · Cited by 334
Zhang, Q., Lou, Y., Yang, J., Wang, J., Feng, J., Zhao, Y., Wang, L., Huang, X., Fu, Q., Ye, M., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318912 · Cited by 326
Zhao, S., Ren, S., Jiang, T., Zhu, B., Li, X., Zhao, C., Jia, Y., Shi, J., Zhang, L., Liu, X., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0640 · Cited by 320
Self-citationRestricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
Renner, K., Bruss, C., Schnell, A., Koehl, G., Becker, H. M., Fante, M., Menevse, A.-N., Kauer, N., Blazquez, R., Hacker, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.068 · Cited by 306
FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution
Newman, A. M., Bratman, S. V., Stehr, H., Lee, L. J., Liu, C. L., Diehn, M., & Alizadeh, A. A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu549 · Cited by 303
Wei, X., Jiang, Y., Zhang, X., Feng, S., Zhou, B., Ye, X., Xing, H., Xu, Y., Shi, J., Guo, W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02184 · Cited by 285
Self-citationIntegrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
Gao, Q., Zhu, H., Dong, L., Shi, W., Chen, R., Song, Z., Huang, C., Li, J., Dong, X., Zhou, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.038 · Cited by 279
Self-citationCamrelizumab: First Global Approval
Markham, A., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01167-0 · Cited by 265
Clark, T., Maximin, S., Meier, J., Pokharel, S., & Bhargava, P. (2015) · Current Problems in Diagnostic Radiology · doi:10.1067/j.cpradiol.2015.04.004 · Cited by 246
Zhu, X.-D., Huang, C., Shen, Y.-H., Ji, Y., Ge, N.-L., Qu, X.-D., Chen, L., Shi, W.-K., Li, M.-L., Zhu, J.-J., et al. (2021) · Liver Cancer · doi:10.1159/000514313 · Cited by 234
Quantitative proteomic analysis of single pancreatic islets
Waanders, L. F., Chwalek, K., Monetti, M., Kumar, C., Lammert, E., & Mann, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908351106 · Cited by 215
Zhou, J., Wang, C., Lin, G., Xiao, Y., Jia, W., Xiao, G., Liu, Q., Wu, B., Wu, A., Qiu, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2299 · Cited by 149
Self-citationDamotte, D., Warren, S., Arrondeau, J., Boudou-Rouquette, P., Mansuet-Lupo, A., Biton, J., Ouakrim, H., Alifano, M., Gervais, C., Bellesoeur, A., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2100-3 · Cited by 148
von Felden, J., Craig, A. J., Garcia-Lezana, T., Labgaa, I., Haber, P. K., D’Avola, D., Asgharpour, A., Dieterich, D., Bonaccorso, A., Torres-Martin, M., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01519-1 · Cited by 136
Chen, V. L., Xu, D., Wicha, M. S., Lok, A. S.-F., & Parikh, N. D. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.04.019 · Cited by 132
Qin, S., Ren, Z., Feng, Y.-H., Yau, T., Wang, B., Zhao, H., Bai, Y., Gu, S., Li, L., Hernandez, S., et al. (2021) · Liver Cancer · doi:10.1159/000513486 · Cited by 127
Kudo, M., Motomura, K., Wada, Y., Inaba, Y., Sakamoto, Y., Kurosaki, M., Umeyama, Y., Kamei, Y., Yoshimitsu, J., Fujii, Y., et al. (2021) · Liver Cancer · doi:10.1159/000514420 · Cited by 101
Cauwels, A., Van Lint, S., Paul, F., Garcin, G., De Koker, S., Van Parys, A., Wueest, T., Gerlo, S., Van der Heyden, J., Bordat, Y., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1980 · Cited by 97
Zhong, J., Peng, N., You, X., Ma, L., Xiao, X., Wang, Y., Gong, W., Wu, F., Xiang, B., & Li, L.-Q. (2017) · Oncotarget · doi:10.18632/oncotarget.15433 · Cited by 92
Self-citationImproved indel detection in DNA and RNA via realignment with ABRA2
Mose, L. E., Perou, C. M., & Parker, J. S. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz033 · Cited by 91
Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor
Vitiello, G. A., Bowler, T. G., Liu, M., Medina, B. D., Zhang, J. Q., Param, N. J., Loo, J. K., Goldfeder, R. L., Chibon, F., Rossi, F., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124108 · Cited by 91
Yang, T., Lin, C., Zhai, J., Shi, S., Zhu, M., Zhu, N., Lu, J., Yang, G.-S., & Wu, M. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1188-0 · Cited by 86
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression
Cai, X., Wei, B., Li, L., Chen, X., Liu, W., Cui, J. T., Lin, Y., Sun, Y., Xu, Q., Guo, W., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106858 · Cited by 58
Wang, S., Shi, H., Liu, T., Li, M., Zhou, S., Qiu, X., Wang, Z., Hu, W., Guo, W., Chen, X., et al. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.09.17 · Cited by 55
Fujii, Y., Ono, A., Hayes, C. N., Aikata, H., Yamauchi, M., Uchikawa, S., Kodama, K., Teraoka, Y., Fujino, H., Nakahara, T., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02016-3 · Cited by 52
Na, K. J., Choi, H., Oh, H. R., Kim, Y. H., Lee, S. B., Jung, Y. J., Koh, J., Park, S., Lee, H. J., Jeon, Y. K., et al. (2020) · Theranostics · doi:10.7150/thno.48954 · Cited by 51
Huang, M., He, M., Guo, Y., Li, H., Shen, S., Xie, Y., Li, X., Xiao, H., Fang, L., Li, D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3840 · Cited by 42
Self-citationLiquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy
Maravelia, P., Silva, D. N., Rovesti, G., Chrobok, M., Stal, P. I., Lu, Y., & Pasetto, A. (2021) · Cancers · doi:10.3390/cancers13174334 · Cited by 39
Xiang, X., Zhong, J., Wang, Y.-Y., You, X., Ma, L., Xiang, B., & Li, L. ‐. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1621-6 · Cited by 34
Hsu, C., Lu, S., Abbas, A., Guan, Y., Zhu, A. X., Aleshin, A. A., Lee, K.-H., Lee, M. S., Mahipal, A., Ryoo, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3531 · Cited by 34
Liu, C., Xing, W., Si, T., Yu, H., & Guo, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.20140 · Cited by 28
Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer
Hou, S., Pan, Z., Hao, X., Hang, Q., & Ding, Y. (2021) · Cancers · doi:10.3390/cancers13205162 · Cited by 24
Sun, T., Ren, Y., Kan, X., Chen, L., Zhang, W., Yang, F., & Zheng, C. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.607520 · Cited by 15
Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review
Gatteschi, L., Iannopollo, M., & Gonfiotti, A. (2021) · Life · doi:10.3390/life11101036 · Cited by 12
Molecular profiling by circulating tumor DNA (ctDNA) and benefit from anti-PD-1 in HCC.
Pestana, R. C., Abugabal, Y. I., Xiao, L., Hassan, M. M., Hassan, R. A. W., Girard, L., Raghav, K. P. S., Morris, J. S., Rashid, A., Qayyum, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e15679 · Cited by 2
Cited by
Shen, K.-Y., Zhu, Y., Xie, S.-Z., & Qin, L.-X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01549-2 · Cited by 247
Self-citationChan, S. L., Sun, H.-C., Xu, Y., Zeng, H., El-Serag, H. B., Lee, J. M., Schwartz, M. E., Finn, R. S., Seong, J., Wang, X. W., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01042-6 · Cited by 215
Self-citationImmune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 164
Self-citationClinical Circulating Tumor DNA Testing for Precision Oncology
Kim, H., & Park, K. U. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1026 · Cited by 135
Tabrizian, P., Holzner, M. L., Ajmera, V. H., Kim, A. K., Zhou, K., Schnickel, G. T., Torosian, K., Hoteit, M. A., Marino, R., Li, M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.003 · Cited by 109
Metadata
- Authors
- Xia, Y., Tang, W., Qian, X., Li, X., Cheng, F., Wang, K., Zhang, F., Zhang, C., Li, D., Song, J., Zhang, H., Zhao, J., Yao, A., Wu, X., Wu, C., Ji, G., Liu, X., Zhu, F., Qin, L., Xiao, X., Deng, Z., Kong, X., Li, S., Yu, Y., Xi, W., Deng, W., Qi, C., Liu, H., Pu, L., Wang, P., & Wang, X.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China
- Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- Jiangsu Province Hospital (CN)
- Simcere Pharmaceutical (China) (CN)
- Corresponding author
- Xia, Yongxiang
- Pu, Liyong
- Wang, Ping
- Wang, Xuehao
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2022-04
- Volume
- 10
- Issue
- 4
- Pages
- e004656
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC8981365
- OpenAlex
- W4224325284
- Cited by
- 228
- References
- 68
- Citations by year
- 2026: 49 · 2025: 61 · 2024: 60 · 2023: 47 · 2022: 11
- FWCI
- 26.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82070676)
- National Natural Science Key Foundation of China (31930020)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- camrelizumab, apatinib, hepatocellular carcinoma, neoadjuvant therapy, adjuvant therapy, perioperative immunotherapy, resectable liver cancer, tumor immune microenvironment, dendritic cell infiltration, circulating tumor DNA, proteomics, predictive biomarkers, relapse-free survival
- MeSH terms
- Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Neoplasm Recurrence, Local, Pyridines, Proteomics, Tumor Microenvironment, Perioperative Period, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.